Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy

BACKGROUND: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but still many do not benefit from this line of treatment. A lack of tumor-infiltrating T cells is a common reason for therapy failure but also a loss of intratumoral dendritic cells (DCs) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Prokopi, Anastasia, Tripp, Christoph H, Tummers, Bart, Hornsteiner, Florian, Spoeck, Sarah, Crawford, Jeremy Chase, Clements, Derek R, Efremova, Mirjana, Hutter, Katharina, Bellmann, Lydia, Cappellano, Giuseppe, Cadilha, Bruno L, Kobold, Sebastian, Boon, Louis, Ortner, Daniela, Trajanoski, Zlatko, Chen, Suzie, de Gruijl, Tanja D, Idoyaga, Juliana, Green, Douglas R, Stoitzner, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789456/
https://www.ncbi.nlm.nih.gov/pubmed/33408092
http://dx.doi.org/10.1136/jitc-2020-000832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789456/
https://www.ncbi.nlm.nih.gov/pubmed/33408092
http://dx.doi.org/10.1136/jitc-2020-000832

Ejemplares similares